StemEdit™ Gene Edited Research iPSCs
Off-the-shelf hypoimmune cell lines
Off-the-shelf hypoimmune cell lines
REPROCELL has developed high-quality HLA knockout iPSC lines using StemEdit—our state-of-the-art genome editing technology, utilizing a proprietary nuclease system. is also well-suited for clinical gene-editing projects.
We offer the following two products to meet the research needs of our customers:
B2M Knockout iPSC Line:
StemEdit™ Human iPSC non-HLA class 1
(B2M Homo KO)
suppresses HLA class 1 expression
StemEdit™ Human iPSC non-HLA class 1
(B2M Homo KO)
(cat. no. RCRP044E)
B2M/CIITA Double Knockout iPSC Line:
StemEdit™ Human iPSC non-HLA class 1/2
(B2M/CIITA Homo double KO)
suppresses both HLA class 1 and HLA class 2 expression
StemEdit™ Human iPSC non-HLA class 1/2
(B2M/CIITA Homo double KO)
(cat. no. RCRP043E)
By using our cell lines, you can immediately start your research using HLA knockout iPSCs without the hassle of editing iPSC lines yourself. In both cell lines, either one or both alleles (homozygous) of the target genes (B2M, CIITA) are knocked out and this reliably suppresses HLA expression.
The introduction of the new hypoimmune StemEdit™ Human iPSC lines marks a significant milestone in advancing immune research and regenerative medicine. By enabling researchers to study and manipulate immune cell interactions with unprecedented precision, these cell lines exemplify REPROCELL's commitment to empowering scientific discovery. We will continue to innovate and provide world-class tools to support breakthroughs in cell therapy and immunology.
— Dr. Chikafumi Yokoyama, CEO of REPROCELL Inc.
StemEdit Human iPSC non-HLA class 1 (B2M Homo KO) and non-HLA class 1/2 (B2M/CIITA Homo double KO) cells were cultured using NutriStem hPSC XF Medium (01-0005) on iMatrix-511 (NP892-011). Pluripotency for both cell lines was confirmed by the strong expression of Nanog, Oct3/4, and SSEA4.
Below: (A.) stained B2M Homo KO cells; (B.) B2M/CIITA Homo double KO cells.
A
B
HLA class 1 expression levels in both strains and the parent strain (VCT-37-F35) were evaluated by flow cytometry analysis using an anti-HLA-ABC antibody. HLA class I expression was confirmed in the parent strain, and HLA class I expression was significantly suppressed in B2M/CIITA Homo double KO (RCRP043E) and B2M Homo KO (RCRP044E), where the B2M gene was knocked out.
Cat. No. | Strain ID | Donor Race | Donor Sex | Donor Age | Donor Clinical Status |
Reprogramming |
Gene Editing Technology | Tissue Source |
RCRP044E | StemRNA™ Clinical iPSC Clone VCT-37-F35 | Caucasian | Female | 23 | Healthy | StemRNA™ Clinical Technology
|
StemEdit™ (proprietary nuclease system)
|
Fibroblasts
|
RCRP043E | StemRNA™ Clinical iPSC Clone VCT-37-F35 | Caucasian | Female | 23 | Healthy | StemRNA™ Clinical Technology |
StemEdit™ |
Fibroblasts
|
The StemRNA Clinical-grade iPSC line VCT-37-F35, established by REPROCELL, is used as the parent line for the preparation of the StemEdit HLA knockout iPSC lines. Our clinical-grade iPSCs have the following features.
Our clinical-grade iPSCs are at the forefront of regenerative medicine, empowering companies and research institutes globally to develop innovative therapies.
A prime example is Gameto's Fertilo technology, which leverages our StemRNA™ Clinical Seed iPSC Clones to create high-purity ovarian support cells for ex vivo egg maturation. Fertilo has achieved a significant milestone as the first iPSC-based therapy to receive IND approval and advance to U.S. Phase 3 clinical trials.
The items below are all available from the REPROCELL product catalog:
Want to use iPSCs in a clinical context?
REPROCELL’s scientists manufacture GMP iPSC & iMSC Master Cell Banks (MCBs) that are compliant with the regulatory standards and guidelines of the FDA, EMA, and PMDA.
Discover our clinical stem cell services
GMP iPSC/iMSC MCB Manufacturing – REPROCELL USA
GMP iPSC/MSC MCB Manufacturing – Histocell (Europe Partner Overview)
Discover more
Gene Editing Services
Resources
Latest in Stem Cells
Why mRNA Reprogramming Is the Key to Safer and Faster iPSC Generation?
Discover how mRNA reprogramming enhances the safety, efficiency, and scalability of iPSC generation for therapeutic applications. Explore REPROCELL's innovative technologies and services.
10 June 2025
Breaking Barriers in Women’s Health: The World’s First Live Birth Using Fertilo
Discover how Gameto achieved the world’s first live birth using Fertilo, a revolutionary in vitro oocyte maturation technology. Learn about its stem cell-driven innovation and how it's transforming fertility care for women worldwide.
21 May 2025
Key Challenges in Clinical iPSC Applications: How REPROCELL Helps You Succeed
Overcome key challenges in clinical iPSC applications with REPROCELL's ethical sourcing, advanced reprogramming, and tailored solutions for reliable, scalable therapies.
12 May 2025